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Edited by Barry HalliwellAbstract Mitochondrial neurogastrointestinal encephalomyop-
athy (MNGIE) is an autosomal recessive disease due to ECGF1
gene mutations causing thymidine phosphorylase (TP) deﬁ-
ciency. Analysis of post-mortem samples of ﬁve MNGIE pa-
tients and two controls, revealed TP activity in all control
tissues, but not in MNGIE samples. Converse to TP activity,
thymidine and deoxyuridine were absent in control samples,
but present in all tissues of MNGIE patients. Concentrations
of both nucleosides in the tissues were generally higher than
those observed in plasma of MNGIE patients. Our observations
indicate that in the absence of TP activity, tissues accumulate
nucleosides, which are excreted into plasma.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is a clinically recognizable autosomal recessive
disease characterized by ptosis and ophthalmoparesis, gastro-
intestinal dysmotility, peripheral neuropathy, leukoencepha-
lopathy, and mitochondrial alterations. MNGIE is caused by
mutations in the ECGF1 gene encoding thymidine phosphory-
lase (TP) [1–4]. TP is a cytosolic enzyme that catalyzes the
reversible phosphorolysis of deoxythymidine (dThd) and deox-
yuridine (dUrd) to the corresponding bases, thymine or uracil,
and 2-deoxyribose 1-phosphate [5,6]. Typically, MNGIE pa-
tients have severely reduced TP activity in buﬀy coat (<10%
of the control mean) causing dramatic elevations of plasmaAbbreviations: dUrd, deoxyuridine; MNGIE, mitochondrial neurogas-
trointestinal encephalomyopathy; dThd, thymidine; TP, thymidine
phosphorylase; UP, uridine phosphorylase
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doi:10.1016/j.febslet.2007.06.042dThd (8.6 ± 3.4 lM, mean ± standard deviation; normal
<0.05) and dUrd (14.2 ± 4.4; normal <0.05) [7–10]. Thus, in
this disease, the association of ECGF1 mutations with altered
pyrimidine nucleoside metabolism and a distinct clinical phe-
notype indicate a causal relationship; however, its pathogene-
sis is not fully understood.
One of the hallmarks of MNGIE is somatic alteration of
mitochondrial DNA (mtDNA), namely, depletion, multiple
deletions, and site-speciﬁc point mutations [1,11–13], which
cause variable defects of the mitochondrial respiratory chain
[1,14]. We have hypothesized that, in MNGIE, elevated levels
of dThd and dUrd cause nucleotide pool imbalances that, in
turn, cause mtDNA instability [3,10]. In vitro studies have
conﬁrmed that high concentrations of extracellular dThd
(10–50 lM) alter nucleotide pools both in cytosol and in mito-
chondria, and unbalanced nucleotide pools, in turn, cause
alterations of mtDNA [15,16].
Curiously, deﬁciency of TP, a vital enzyme expressed in most
tissues, preferentially aﬀects extraocular muscles, gastrointesti-
nal system, peripheral nerves, and central nervous system white
matter. To better understand the organ-speciﬁcity of MNGIE,
we have measured TP activity and levels of deoxynucleosides in
post-mortem tissues from MNGIE patients and controls.2. Methods and materials
2.1. Patient and control samples
We analyzed several post-mortem tissues from ﬁve MNGIE patients
previously reported as MN2-01, MN3-01, MN4-02, MN7-02, and
MN29-01 [2,17]. All of the patients manifested the typical clinical
features of MNGIE and their diagnoses were conﬁrmed by measure-
ment of buﬀy coat TP activity and identiﬁcation of ECGF1 mutations
(Table 1). The ages at death were 29–39 years old. Tissues were col-
lected 11–24 h post-mortem and stored at 80 C. Control autopsy tis-
sues from age-matched subjects with similar post-mortem intervals
were obtained from the Brain and Tissue Bank for Developmental Dis-
orders (University of Maryland). Autopsy and biopsy tissues were col-
lected and analyzed under Columbia University Institutional Review
Board approved protocols.
2.2. Measurements of nucleosides
dThd and dUrd levels were assessed by a gradient-elution HPLC
method as previously described [8]. Between 15 and 280 mg of tissue
was homogenized in lysis buﬀer (50 mM Tris–HCl, pH 7.2, containingblished by Elsevier B.V. All rights reserved.
Table 1
Molecular genetic and biochemical features in blood of MNGIE patients whose post-mortem tissues were analyzed in this report
Patient Age at death Gender Age at onset TP mutations Buﬀy coat TP Plasma dThd (lM) Plasma dUrd (lM)
MN2-01 33 M 18 IVS4 +2T > C UND Not determined Not determined
E289A
MN3-01 37 M 18 G145R UND Not determined Not determined
G145R
MN4-02 29 F 15 K222S UND 6.4 Not determined
frameshift
MN7-02 39 F 26 E289A UND 5.7 Not determined
IVS9 1G > C
MN29-01 32 M Infancy G153S UND 5.5 Not determined
G153S
Patients are numbered according to previous publications [2,17]. TP activity in nmol thymine formed/h/mg protein. UND, undetectable.
M.L. Valentino et al. / FEBS Letters 581 (2007) 3410–3414 34111% Triton X-100, 2 mM phenylmethylsulfonyl ﬂuoride, and 0.02% 2-
mercaptoethanol), sonicated, and centrifugated at 2500 · g for
10 min. Supernatants were deproteinized with 0.5 M perchloric acid
and injected into an Alliance high-performance liquid chromatography
(HPLC) apparatus (Waters Corporation) with an Alltima C18NUC re-
versed-phase column (Alltech) at a constant ﬂow rate of 1.5 ml/min
using two buﬀers: eluent A (20 mM potassium phosphate, pH 5.6)
and eluent B (20 mM potassium phosphate–60% methanol, pH 5.6).
Samples were eluted over 110 min with a gradient as follows: 0–
5 min, 100% eluent A; 5–92 min, 100–0% eluent A; 92–93 min, 0–
100% eluent A; and 93–110 min, 100% eluent A.
Absorbance of the eluates was monitored at 267 nm and dThd and
dUrd peaks were quantitated by comparing their peak areas with a cal-
ibration curve obtained with aqueous standards. For deﬁnitive identi-
ﬁcation of dThd and dUrd peaks for each sample, we used a second
aliquot treated with excess of puriﬁed E. coli TP (Sigma) to speciﬁcally
eliminate dThd and dUrd. The detection limit of this method was
0.05 lmol/L for both deoxynucleosides.
2.3. Thymidine phosphorylase activity
TP activity was measured using an HPLC detection method as de-
scribed [18].
Between 30 and 120 mg of frozen tissue was homogenized in lysis
buﬀer and brieﬂy sonicated. Samples were centrifugated at
13000 · g · 30 min at 4 C and 100 lg of protein were incubated with
10 mM dThd in reaction buﬀer (0.1 M Tris–arsenate, pH 6.5), at 37 C
for 1 h, in a total volume of 100 ll. For each sample a blank was also
processed to which dThd was not added. The reaction was stopped by
the addition of 1 ml 0.55 M perchloric acid in all the samples and
10 mM dThd in all the blanks. The supernatants were injected into
the HPLC apparatus described above and eluted, over 20 min, at aTable 2
Levels of deoxythymidine (dThd) and deoxyuridine (dUrd) in tissues of MN
Tissues Patients dThd
pmol/mg tissue nmol/g prot
Mean Range Mean Rang
Small intestine n = 4 21 1.9–40 471 38–92
Occipital white matter n = 4 17 10–33 469 93–88
Peripheral nerve n = 5 14 5.0–28 507 177–1
Muscle n = 4 5.5 2.0–14 102 17–20
Muscle autopsya n = 1 14 – 201 –
Muscle biopsya n = 1 4.8 – 49 –
Liver n = 4 33 9.7–80 384 61–94
Kidney n = 5 18 4.0–30 243 64–39
Heart n = 5 8.3 3.2–13 116 35–27
UND, undetectable.
aSamples from patient MN7-2.constant ﬂow rate of 1.5 ml/min, with 20 mM potassium phosphate–
10% methanol, pH 5.6. The absorbance of the eluate was monitored
at 267 nm and thymine peaks were identiﬁed and quantiﬁed using a
calibration curve. The protein content of the supernatants was deter-
mined using the bicinchoninic acid method [19]. Due to limited
amounts of post-mortem tissues, TP activity was measured in tissues
from only two patients.3. Results
3.1. Levels of thymidine and deoxyuridine are elevated in all
tissues of MNGIE patients
We measured levels of nucleosides in ﬁve clinically aﬀected
tissues (small intestine, peripheral nerve, muscle, occipital
white matter and liver [MN2-01 had cirrhosis, MN4-02 had li-
ver steatosis]) and two unaﬀected tissues (kidney and heart) in
patients and controls (Table 2). In MNGIE patients, all tissues
showed accumulation of dThd and dUrd whereas control tis-
sues had no detectable pyrimidine nucleosides (Table 2). The
highest concentrations of dThd and dUrd were detected in
four of the ﬁve aﬀected tissues: peripheral nerve, small intes-
tine, occipital white matter, and liver while kidney and heart,
two unaﬀected organs and skeletal muscle, a less severely af-
fected tissue, had lower levels of nucleosides (Table 2).
When we compared the concentrations of nucleosides in
biopsy and autopsy muscle of the same MNGIE patient, weGIE patients and controls
dUrd dThd and
dUrd
pmol/mg tissue nmol/g prot Controls
e Mean Range Mean Range
6 18 9.2–27 379 136–630 n = 3 UND
9 22 10–41 498 217–694 n = 4 UND
532 18 6.5–33 467 351–724 n = 3 UND
1 8.0 5.2–16 109 44–223 n = 4 UND
16 – 223 – – –
5.4 – 55 – – –
3 24 11–48 264 88–566 n = 4 UND
6 17 5.2–35 252 102–464 n = 4 UND
8 9.6 3.0–17 138 32–374 n = 2 UND
Table 3
TP activity in nmol thymine formed h1 (mg protein)1, in autopsy and biopsy tissues from MNGIE patients and controls
Patients TP Controls Mean TP (range)
Small intestine n = 2 UND n = 2 1121 (911–1331)
Occipital white matter n = 2 UND n = 2 16 (16–16)
Peripheral nerve n = 2 UND n = 2 34 (33–35)
Muscle n = 2 UND n = 3 55 (51–60)
Muscle biopsy n = 1 UND n = 3 21 (16–27)
Liver n = 2 UND n = 2 1817 (1642–1992)
Kidney n = 2 UND n = 2 234 (226–242)
Heart n = 2 UND n = 2 40 (36–44)
UND, undetectable.
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49 nmol/g prot, dUrd 55 nmol/g prot) than in the post-mortem
(dThd 201, dUrd 223). Nevertheless, the levels in biopsy sam-
ples were within the range of the values found in all the au-
topsy muscles (dThd range 17–201, dUrd range 44–223)
(Table 2). The diﬀerence in nucleoside levels in biopsy and
post-mortem samples may be due to random ﬂuctuations, in-
creased levels in the terminal phase of the illness, or post-mor-
tem accumulations of nucleosides.
3.2. Thymidine phosphorylase activity is deﬁcient in all tissues of
MNGIE patients
TP activity was not detectable in all the autopsy tissues from
two individuals with MNGIE (Table 3), conﬁrming the drastic
reduction of the enzymatic activity found in buﬀy coats of pa-
tients [2,3]. TP activity was detected at low levels in control
muscle, as previously reported [20] and also in kidney an organ
reported to lack this enzyme [21].4. Discussion
MNGIE is a rare autosomal recessive disorder caused by
mutations in the nuclear gene encoding TP [1–3]. Absence of
TP activity causes a generalized metabolic defect characterized
by a dramatic accumulation of TP substrates, dThd and dUrd,
in plasma of MNGIE patients [8–10]. The absence of these
nucleosides in plasma of healthy controls and in asymptomatic
TP mutation carriers [8–10] suggests that the disease develops
due to the toxic eﬀect of dThd and dUrd overload on mtDNA,
as in vitro experiments have demonstrated that high concen-
trations of these nucleosides cause depletion and multiple dele-
tions of mtDNA [15,16].
To date, accumulations of dThd and dUrd in MNGIE pa-
tients have been observed in plasma and urine of MNGIE pa-
tients [7–10]. In one deceased patient, TP dysfunction was
conﬁrmed through demonstration of elevated dThd and dUrd
in skeletal muscle, the only available tissue [22]. Here, we have
measured nucleosides in clinically aﬀected and unaﬀected tis-
sues from autopsies of ﬁve MNGIE patients; levels of dThd
and dUrd were dramatically elevated in all tissues, indicating
that, in MNGIE, nucleoside imbalance is ubiquitous.
In ﬁve of the seven tissues analyzed in patients, concentra-
tions of these nucleosides were higher in tissues than in blood
consistent with the notion that thymidine and deoxyuridine are
cellular by-products, which, in the absence of TP catabolism,
are excreted into extracellular space. We reported mean plas-
ma concentrations of dThd and dUrd in MNGIE patients
were 8.6 and 14.2 lmol/l [8] and observed mean plasma dThdconcentration of 5.9 lM in the subgroup of patients in this
study, while, in contrast, most of the tissues studied here
showed average content of dThd and dUrd higher than
14 pmol/mg tissue (units similar to lmol/l, assuming the den-
sity of the tissues close to 1 g/ml) (Table 2). This diﬀerence in
nucleoside levels may be underestimated, because recovery of
nucleosides from homogenized tissues is likely to be less than
100%, while nucleosides are measured directly in plasma and
therefore completely recovered. We have observed up to two-
fold ﬂuctuations in plasma thymidine levels in clinically stable
MNGIE patients indicating that nucleoside levels vary signiﬁ-
cantly. Furthermore, quantitation of nucleosides in autopsy
tissues may be inaccurate due to post-mortem deoxynucleotide
degradation that might have artifactually exaggerated the in-
crease of nucleoside levels in these samples and contributed
to the wide variation in the results. In fact, when muscle biopsy
and post-mortem muscle samples from a single patient were
analyzed, both dThd and dUrd levels were four-fold higher
in the autopsy, compared to the biopsy suggesting that nucle-
oside measurements in post-mortem tissues may overestimate
levels. Nevertheless, this interpretation is based on studies of
only one patient and is therefore tenuous. This diﬀerence be-
tween the biopsy and autopsy analysis could be due to intra-
individual variation. Analyses of additional muscle biopsies,
which is not possible in this study due to limited tissue avail-
ability, would be important.
Levels of dThd and dUrd in diﬀerent tissues did not corre-
late with the clinical involvement of organs. For example, skel-
etal muscle, which is aﬀected clinically and histologically in
most MNGIE patients, showed the lowest levels of nucleosides
and below levels found in kidney, which is unaﬀected. Liver,
which is inconsistently aﬀected in patients, had dThd and
dUrd levels similar to small intestine, peripheral nerve and
white matter, which are invariably aﬀected in MNGIE. In line
with these observations, previous reports showed no correla-
tion between severity of the symptoms and levels of circulating
dThd and dUrd, when above 3 lM [2,8]. Only patients with
less deleterious mutations in the ECGF1 gene, which cause par-
tial TP dysfunction (10–15% of control mean), accumulate
only modestly increased plasma dThd and dUrd levels (0.5–
1.5 lM), resulting in a later onset of the disease [18].
In MNGIE, post-mitotic cells appear to be preferentially af-
fected. For example, enteric smooth muscle degeneration
causes gastrointestinal dysmotility and skeletal muscle involve-
ment causes proximal limb weakness [1,2,23]. The tissue-spec-
iﬁcity in MNGIE may be attributable to the dependence of
mtDNA replication on the mitochondrial nucleoside salvage
pathway in quiescent cells [15,24,25], energy requirements of
speciﬁc cells, or a combination of both factors.
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lute or virtually complete absence of TP activity found in buﬀy
coat samples. TP activity in these organs was analyzed in sam-
ples from several controls, resulting in variable activities for dif-
ferent tissues. In contrast to several reports that failed to ﬁnd
TP protein in skeletal muscle and kidney in humans
[20,21,26,27], we could clearly detect and quantitate TP activi-
ties in these tissues. The discrepancies between our detection of
TP activity and prior immunohistochemical studies may be re-
lated to the lower sensitivity of antibodies compared to bio-
chemical assays. It is unlikely that uridine phosphorylase
(UP) could have interfered our enzymatic analysis, because hu-
man UP poorly catabolizes thymidine, the substrate used in our
TP assay [28] and, in MNGIE patients, we were unable to de-
tect TP activity in liver and kidney, tissues that express UP [29].
We could not identify correlations between the magnitude of
normal TP activities and elevations of nucleosides in tissues of
MNGIE patients. For example, normal small intestine has
very high TP activity (1121 nmol thymine formed/h/mg prot)
while loss of TP function in this tissue caused moderate in-
creases in dThd (21 pmol/mg tissue) and dUrd (18 pmol/mg
tissue) which are similar to levels in peripheral nerve of
MNGIE patients, dThd (14 pmol/mg tissue) and dUrd
(18 pmol/mg tissue), despite the relatively low TP activity
(34 nmol thymine formed/h/mg prot) in normal peripheral
nerve (Table 2). This lack of correlation suggests that the func-
tion of high TP activity in organs is not merely catabolism of
locally produced nucleosides, but rather systemic clearance of
dThd and dUrd. In support of this notion, we and others have
observed high TP activities in highly vascularized tissues, liver,
small intestine, kidney and placenta, which are exposed to
large volumes of blood [30]; therefore, the role of TP, at least
in some tissues, may be systemic clearance of dThd and dUrd.
Pharmacokinetics studies indicate that in humans, dThd is
distributed in the total body water volume [31]. The rapid
equilibration of dThd in tissues may be facilitated by nucleo-
side transporters, which have been identiﬁed in plasma mem-
brane of many cells types [32]. Furthermore, studies of
cultured cells have demonstrated a rapid passage of dThd
across both plasma and mitochondrial membranes [33], which
may be mediated by human equilibrative nucleoside trans-
porter 1 (hENT1), which is present in plasma membranes of
liver, spleen, adipose cells, brain, colon and other tissues,
and has also been identiﬁed in the inner membrane of mito-
chondria [34,35]. Consistent with these ﬁndings, our results
show that, in MNGIE, dysfunction of TP produces a general-
ized increase of its substrates, dThd and dUrd, in all organs.
Further studies are necessary to determine the intramitochon-
drial levels of these nucleosides and their potential eﬀects on
mitochondrial nucleotide pools and mtDNA maintenance.
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